Inverse psoriasis is considered to be a rare variant of plaque-type psoriasis and is associated with significantly impaired quality of life. Clinical manifestations and treatment options are somewhat different for each subtype. Identifying genetic variants that contribute to the susceptibility of different types of psoriasis might improve understanding of the etiology of the disease. Since we have no current knowledge about the genetic background of inverse psoriasis, whole exome sequencing was used to comprehensively assess genetic variations in five patients with exclusively inverse lesions. We detected six potentially pathogenic rare (MAF < 0.01) sequence variants that occurred in all investigated patients. The corresponding mutated genes were FN1, FBLN1, MYH7B, MST1R, RHOD, and SCN10A. Several mutations identified in this study are known to cause disease, but roles in psoriasis or other papulosquamous diseases have not previously been reported. Interestingly, potentially causative variants of established psoriasis-susceptibility genes were not identified. These outcomes are in agreement with our hypothesis that the inverse subtype is a different entity from plaque-type psoriasis.

Journal of the European Academy of Dermatology and VenereologyVolume 34, Issue 9 p. e523-e524 Letter To The Editor Anti-interleukin-6 receptor therapy-induced cutaneous symptoms resembling purpura fulminans in a patient with seropositive rheumatoid arthritis G.R. Nagy, Corresponding Author G.R. Nagy n.geza@outlook.com orcid.org/0000-0002-3876-0422 Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary Correspondence: G.R. Nagy. E-mail: n.geza@outlook.comSearch for more papers by this authorE. Varga, E. Varga Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this authorL. Kovács, L. Kovács Department of Rheumatology and Immunology, University of Szeged, Szeged, HungarySearch for more papers by this authorI. Németh, I. Németh Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this authorE. Varga, E. Varga Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this authorL. Kemény, L. Kemény Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this authorZ. Bata-Csörgő, Z. Bata-Csörgő Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this author G.R. Nagy, Corresponding Author G.R. Nagy n.geza@outlook.com orcid.org/0000-0002-3876-0422 Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary Correspondence: G.R. Nagy. E-mail: n.geza@outlook.comSearch for more papers by this authorE. Varga, E. Varga Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this authorL. Kovács, L. Kovács Department of Rheumatology and Immunology, University of Szeged, Szeged, HungarySearch for more papers by this authorI. Németh, I. Németh Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this authorE. Varga, E. Varga Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this authorL. Kemény, L. Kemény Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this authorZ. Bata-Csörgő, Z. Bata-Csörgő Department of Dermatology and Allergology, University of Szeged, Szeged, HungarySearch for more papers by this author First published: 10 April 2020 https://doi.org/10.1111/jdv.16442Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume34, Issue9September 2020Pages e523-e524 RelatedInformation

Introduction: Phototherapy has long been used for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. The most frequent treatment approach utilizes ultraviolet (UV) light, however, recently, different lasers and low-level light therapies (LLLT) emitting wavelengths in the spectrum of the visible light have also been tried for the treatment of inflammatory skin diseases with variable success. Areas covered: This review provides an update on the different forms of phototherapy used for the treatment of psoriasis and atopic dermatitis. The proposed mechanism of action of the different phototherapeutical approaches are covered, including the immunosuppressive effect of UV light, the anti-inflammatory effect of vascular lasers and the LLLT induced photobiomodulation. The clinical efficacy of the different treatment options is also discussed. Expert opinion: Based on the efficacy and safety, NB-UVB represents the gold standard for treating psoriasis and atopic dermatitis. The UVB excimer laser and excimer lamp might be the best option for clearing localized therapy-resistant lesions. Home UV phototherapy systems might promote treatment adherence and better compliance of the patients. Vascular lasers, IPLs and LLLT, however, can not currently be recommended for the treatment of inflammatory skin diseases because of the lack of well-controlled studies.

treatment of the atopic dermatitis. Their antiinflammatory effect is com-parable to moderate-potency corticosteroids, and can be used for long-term therapy, since local and systemic side effects ob-served during the treatment with corticosteroids, do not oc-cur. Their use is particularly advantageous for the treatment of facial areas and body folds, in which areas local corticosteroids cause side effects relatively quickly. In the treatment of atopic dermatitis with frequent flares, the so-called proactive treatment is suggested, where local calcineurin inhibitors are applied twice a week to the clinically asymptomatic skin, in order to maintain the patients symptom-free.